Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $57.00 at HC Wainwright

Apellis Pharmaceuticals (NASDAQ:APLS) had its target price cut by HC Wainwright from $83.00 to $57.00 in a research note published on Wednesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ Q4 2024 earnings at ($0.49) EPS, FY2024 earnings at ($1.79) EPS, Q1 2025 earnings at ($0.55) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.73) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at $0.88 EPS and FY2028 earnings at $2.61 EPS.

APLS has been the subject of a number of other research reports. Royal Bank of Canada restated a “sector perform” rating and set a $25.00 target price on shares of Apellis Pharmaceuticals in a research report on Monday, November 4th. Robert W. Baird cut their target price on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating for the company in a research report on Monday, September 23rd. UBS Group cut their price objective on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Jefferies Financial Group reissued a “buy” rating and issued a $80.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday, July 31st. Finally, Evercore ISI raised shares of Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Six research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $51.06.

Apellis Pharmaceuticals Stock Up 4.3 %

APLS stock opened at $29.98 on Wednesday. The company has a current ratio of 4.36, a quick ratio of 4.18 and a debt-to-equity ratio of 1.91. The company has a market cap of $3.73 billion, a P/E ratio of -14.77 and a beta of 0.87. The company’s 50-day moving average price is $31.02 and its 200 day moving average price is $36.94. Apellis Pharmaceuticals has a 52 week low of $24.34 and a 52 week high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business’s revenue was up 78.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.17) EPS. On average, research analysts expect that Apellis Pharmaceuticals will post -1.5 earnings per share for the current fiscal year.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares in the company, valued at $3,623,000. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Assenagon Asset Management S.A. grew its stake in Apellis Pharmaceuticals by 191.9% during the third quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock worth $61,845,000 after buying an additional 1,409,707 shares during the period. Fiera Capital Corp grew its stake in Apellis Pharmaceuticals by 47.7% during the second quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock worth $53,750,000 after buying an additional 452,753 shares during the period. Iron Triangle Partners LP purchased a new position in shares of Apellis Pharmaceuticals in the first quarter valued at $32,329,000. Bank of New York Mellon Corp boosted its stake in shares of Apellis Pharmaceuticals by 6.9% in the second quarter. Bank of New York Mellon Corp now owns 345,195 shares of the company’s stock valued at $13,242,000 after purchasing an additional 22,273 shares during the period. Finally, Altitude Crest Partners Inc. boosted its stake in shares of Apellis Pharmaceuticals by 88.7% in the first quarter. Altitude Crest Partners Inc. now owns 287,277 shares of the company’s stock valued at $16,886,000 after purchasing an additional 135,077 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).